No quarterly revenue total was found in INTENSITY THERAPEUTICS, INC.'s SEC filings.
Intensity Therapeutics, Inc. (INTS) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). As of Sep 30, 2026 it held $8.5 million in cash and investments and $87,000 in total debt.
Revenue
—
Net income
$-3.54M
-32.7% vs year-ago quarter
Operating cash flow
$-2.50M
-4.7% vs year-ago quarter
Free cash flow
—
EPS
$-1.09
+29.7% vs year-ago quarter
Dividend per share
None
Shares outstanding
3.30M
-94.5% vs year-ago quarter
Net cash
$8.41M
Q3 FY2026
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- INTS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Shelton, CT
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1567264
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$3.6M | -$3.1M | -$2.5M | -$3.1M | -$2.7M |
| Net income | -$3.5M | -$3.0M | -$2.4M | -$3.1M | -$2.7M |
| Diluted EPS | -$1.09 | -$1.11 | -$0.96 | -$1.32 | -$1.55 |
| Operating cash flow | -$2.5M | -$2.3M | -$1.8M | -$2.4M | -$2.4M |
| Total assets | $10.3M | $11.5M | $12.3M | $14.1M | $9.6M |
| Total liabilities | $2.6M | $2.3M | $2.3M | $2.2M | $2.4M |
| Stockholders' equity | $7.7M | $9.2M | $10.0M | $11.9M | $7.2M |
| Cash and investments | $8.5M | $9.5M | $10.2M | $11.9M | $7.1M |
| Total debt | $87,000 | $95,000 | $102,000 | $110,000 | $118,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 16, 2026 | Jun 16, 2026 |
| 8-K |
Current report
Results of operations
|
May 7, 2026 | May 7, 2026 |
All 246 Intensity Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.